Snap a pic, beat diabetes: AI food app trial aims to revolutionize blood sugar control
NCT ID NCT07533604
First seen Apr 17, 2026 · Last updated Jun 17, 2026 · Updated 12 times
Summary
This pilot study tests whether an AI-powered app called SnapD, which analyzes photos of Thai food to estimate nutrition, can help people with type 2 diabetes and overweight better control their blood sugar. About 45 adults will use the app alone or with a continuous glucose monitor for 8 weeks. The goal is to see if these digital tools improve HbA1c levels compared to standard diabetes education.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medicine, Ramathibodi Hospital,
RECRUITINGBangkok, Bangkok, 10400, Thailand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.